00660 WAI CHUN BIOTEC
- 0.140
- -0.010-6.67%
WAI CHUN BIOTEC News
Wei Jun Biotechnology (00660.HK): Lin Qiji resigns as company secretary
Gelonghui, May 21丨Weijun Biotechnology (00660.HK) announced the resignation of Mr. Lin Qiji as company secretary and authorized representative, effective May 21, 2024.
Wai Chun Biotechnology (00660) appoints Lam Kai-ki as company secretary and authorized representative
Zhitong Finance App News, Wei Jun Biotechnology (00660) announced that Li Huifang has resigned as the company's company secretary and no longer serves as the company's authorized representative. Lin Qiji has been appointed as the company's secretary and authorized representative, effective March 28, 2024.
WAI CHUN BIOTEC: Interim Report 2023/24
Wai Chun Bio-Technology's Fiscal H1 Attributable Loss Narrows
Wai Chun Bio-Technology's (HKG:0660) attributable loss narrowed to HK$6.7 million, or HK$0.0393 per share, in the half-year ended Dec. 31, 2023, from HK$7.8 million, or HK$0.0457 per share, in the yea
Weijun Biotechnology (00660) announced interim results. Shareholders' share loss of HK$6.734 million narrowed 14.01% year-on-year
According to the Zhitong Finance App, Weijun Biotechnology (00660) announced results for the six months ended December 31, 2023. The group achieved revenue of HK$190 million during the period, a year-on-year decrease of 53.01%; the loss due to company owners during the period was HK$6.734 million, a year-on-year decrease of 14.01%; the basic loss per share was HK$3.93. According to the announcement, the decline in revenue was due to a decrease in market consumption and demand during the period.
WAI CHUN BIOTEC: INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Weijun Biotechnology (00660.HK) will hold a board meeting on February 29 to approve the interim results
Gelonghui, Feb. 19 | Weijun Biotechnology (00660.HK) announced that the company will hold a board meeting on February 29, 2024 to consider and approve the unaudited interim results announcement and release of the company and its subsidiaries for the six months ended December 31, 2023.
Wai Chun Biotechnology (00660.HK): Lee Wai Fong Appointed as Secretary and Authorised Representative
Gelonghui, Feb. 15 | Weijun Biotechnology (00660.HK) announced that He Xiaoping has proposed to resign as company secretary and terminated his position as authorized representative of the company under section 3.05 of the Hong Kong Stock Exchange Limited securities listing rules. Li Huifang has been appointed as company secretary and authorized representative with effect from February 15, 2024.
Weijun Biotechnology (00660) appoints Lee Wai Fong as company secretary and authorized representative
Weijun Biotechnology (00660) announced that He Xiaoping has resigned as the company's company secretary and terminated the company's authorization...
Winding-Up Petition Against Wai Chun Bio-Technology Withdrawn
The High Court of Hong Kong ordered the withdrawal of a winding-up petition against Wai Chun Bio-Technology (HKG:0660) after settling with the petitioner, JAN Financial Press. JAN filed the petition a
Weijun Biotechnology (00660): The winding-up petition was withdrawn
Weijun Biotechnology (00660) issued an announcement. The company and the petitioner have submitted a petition on November 28, 2023...
Guoxin Securities's 24-year chemical strategy: the economy is expected to bottom out and rebound, optimistic about the direction of upstream core resource products and downstream emerging chemicals
We are more optimistic about the investment direction of upstream core resource products and emerging chemicals where downstream demand is expected to continue to grow.
Business Society: The slight adjustment in phosphoric acid prices is expected to be weak in the short-term market, mainly
As of November 22, the average domestic reference price of 85 caloric phosphoric acid was 7080 yuan/ton, down nearly 2% from the average reference price of 7,200 yuan/ton on November 1.
Summary of the Bank of China Securities Basic Chemical Report for the Third Quarter of '23: Low profit levels are expected to stabilize the demand side or continue to improve
The Zhitong Finance app learned that Bank of China Securities released a research report saying that under the influence of factors such as weak downstream demand, the overall profitability of the basic chemical industry in the first three quarters of 2023 fell to a recent low level, and the performance of some sub-industries improved in 23Q3
Summary of China Merchants Securities Basic Chemical's three-quarter report in '23: The business cycle is expected to bottom out and is optimistic about marginal demand recovery
The Zhitong Finance App learned that China Merchants Securities released a research report saying that on the supply side, under the guidance of carbon peak and carbon neutrality policies, supply in the chemical industry will continue to be restricted, and the elimination of lagging inefficient production capacity will further concentrate market share on leading companies; on the demand side, with inventory pressure gradually easing and the macroeconomic environment expected to improve marginally, demand in the basic chemical industry is expected to continue to improve.
Wai Chun Bio-Technology Names Controlling Shareholder's Son as Chairman/CEO
Wai Chun Bio-Technology (HKG:0660) appointed Lam Ka Chun, an executive director, as its chairman and chief executive. Lam will take on the roles in addition to his responsibilities as chairman and CEO
Weijun Biotechnology (00660): Lin Jiajun appointed as Chairman of the Board
Weijun Biotechnology (00660) announced that in addition to holding this position, Lin Jiajun, the current executive director of the company, has also been appointed...
WAI CHUN BIOTEC: Annual Report 2022/23
Weijun Biotechnology (00660.HK) received a winding-up petition
Glonghui, Oct. 25, 丨 Wei Jun Biotechnology (00660.HK) announced that on September 29, 2023, the Company received a winding-up petition from Anlin Financial Printing Co., Ltd. to the Court of First Instance of the High Court of Hong Kong Special Administrative Region for expenses and accrued interest totaling HK$333,502 under the “Companies (Liquidation and Miscellaneous Provisions) Ordinance”, Chapter 32 of the Hong Kong Laws. A petition was filed with the High Court of Hong Kong only as an application for the winding-up of the company. The High Court of Hong Kong did not issue a winding-up order to wind up the company. The first hearing of the petition is scheduled for the morning of December 6, 2023
Wai Chun Bio-Technology Incurs Loss in Fiscal Year 2023
Wai Chun Bio-Technology (HKG:0660) logged a loss attributable to the owners of HK$15.4 million for the year ended June 30, versus HK$21.5 million in the 18-month period ended June 2022. Loss per share
Analysis
Price Target
No Data
